Chiusura precedente | 0,1000 |
Aperto | 0,1000 |
Denaro | 0,0000 |
Domanda | 0,1500 |
Prezzo d'esercizio | 15,00 |
Scadenza | 2024-07-19 |
Min-Max giorno | 0,1000 - 0,1000 |
Contratto - Min-Max | N/D |
Volume | |
Open Interest | 2,02k |
BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with rare diseases of the immune system, today announced the closing of a $115 million loan facility with Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”). The company also announced that it drew down $22.5 million upon the transaction’s closing. “This expanded loan facility creates significant financial flexibility for X4 a
LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that the Company has entered into a term loan agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $50 million. Kabir Nath, COMPASS Pathways Chief Executive Officer said, “COMPASS is pleased to partner with Hercules for this source of non-dilutive financing to support our COMP360 phas